Earnings ·
Reports Q3 net revenue of $180.3 million, raises full-year total revenue guidance to $715M-$730M
BCRXBiocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals reported third-quarter 2026 total net revenue of $180.3 million and ORLADEYO net revenue of $174.8 million. The company achieved an operating profit of $53.3 million ($86.5 million non-GAAP) and net income of $37.9 million ($71.1 million non-GAAP). Management raised full-year 2026 total revenue guidance to $715 million–$730 million from the previous range of $690 million–$715 million, while maintaining ORLADEYO revenue guidance at $625 million–$645 million. The company also received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older and transitioned its specialty pharmacy distribution to CareMed. BioCryst Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema and other rare diseases.